Treatment for bk polyomavirus infection
AssigneeAnsun Biopharma, Inc.
InventorRonald D. Moss
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel compositions and methods for treating infection by a viral pathogen, e.g., a BK or JC polyomavirus, using agents having sialidase activity. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen.
Claims50
A method for treating infection by a polyomavirus in a subject, the method comprising administering to the subject an effective amount of an agent having sialidase activity.
A method of reducing the risk or severity of an infection by a polyomavirus in a subject, the method comprising administering to the subject an effective amount of an agent having sialidase activity.
A method of treating an infection by a BK polyomavirus or a BK polyomavirus-associated disorder in a subject, the method comprising administering to the subject an effective amount of an agent having sialidase activity.
A method of reducing the risk or severity of an infection by BK polyomavirus or a BK polyomavirus-associated disorder in a subject, the method comprising administering to the subject an effective amount of an agent having sialidase activity.
A method of treating an infection by a JC polyomavirus or a disorder caused by JC polyomavirus in a subject, the method comprising administering to the central nervous system of the subject an effective amount of an agent having sialidase activity.
A method of reducing the risk or severity of an infection by a JC polyomavirus or a disorder caused by JC polyomavirus in a subject, the method comprising administering to the subject an effective amount of an agent having sialidase activity.
Dependencies are inferred from the claim text.